

Summary Report of Consolidated Financial Results

August 10, 2004

For the Three Months Period ended June 30, 2004 (Fiscal Year ending March 31, 2005)

Company name: **NIPRO CORPORATION**

Code No.:8086 TSE/OSE-1st Section

(URL: <http://www.nipro.co.jp/>)

Representative: Minoru Sano, President and Representative Director

Contact: Akihiko Yamabe, Director, General Manager of Accounting & Corporate Planning Division
TEL (06) 6372-2331

1. Matters related to the preparation of quarterly financial summary
 - (1)Adoption of simplified accounting treatments: N/A
 - (2)Difference in the method of accounting recognition from the most recent fiscal year: N/A
 - (3)Changes in the scope of consolidation and application of the equity method: Adoption
(Content: Consolidation (New) 1)
2. Business results and financial position for the three months ended June 30, 2004 of the Fiscal Year ending March 31,2005.(From April 1, 2004 to June 30, 2004)

(1)Results of Operations (Note: Amounts are rounded off per one million yen)

	Net Sales		Operating Income		Recurring Income		Net (Quarter) Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2004	47,271	2.3	3,397	(9.0)	3,164	(2.5)	1,734	16.4
Three months ended June 30, 2003	46,191	-	3,731	-	3,243	-	1,490	-
Fiscal Year ended March 31, 2004	188,700		12,557		9,539		4,216	

	Basic Earnings per Share	Diluted Earnings per Share
	Yen	Yen
Three months ended June 30, 2004	27.26	-
Three months ended June 30, 2003	23.41	-
Fiscal Year ended March 31, 2004	64.90	-

(Note) Percentage for net sales, operating income, etc. represents the ratio of change over from same period of the previous fiscal year.

[Supplementary information on the consolidated results of operations]

The Japanese economy for this three months period generated the improved mood of recovery, led by exports and capital investments, followed by the new personal consumptions.

Under such conditions, Nipro has focused on sales activities to improve business performance.

As a result, net sales for the three months ended June 30, 2004 increased by 2.3% from same period of the previous fiscal year to ¥47,271 million, primarily due to increase in sales of pre-filled syringes at the Pharmaceutical division.

On the other hand, operating income decreased by 9.0% from same period of the previous fiscal year to ¥3,397 million, due to the rise in the ratio of cost of sales to net sales by intensification of price competition and the increase in selling, general, administrative expenses and recurring income decreased by 2.5% from same period of the previous fiscal year to ¥3,164 million.

Net (Quarter) income increased by 16.4% from same period of the previous fiscal year to 1,734 million, mainly due to decrease in extraordinary losses.

(2)Financial Position

	Total Assets	Shareholders' Equity	Ratio of Shareholders' Equity to Total Assets	Shareholder' Equity per Share
	Millions of yen	Millions of yen	%	yen
Three months ended June 30, 2004	276,461	91,692	33.2	1,441.53
Three months ended June 30, 2003	253,469	84,896	33.5	1,334.03
Fiscal Year ended March 31, 2004	279,701	94,711	33.9	1,487.50

Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Three months ended June 30, 2004	488	(2,132)	1,873	42,441
Three months ended June 30, 2003	2,506	(3,120)	564	29,467
Fiscal Year ended March 31, 2004	15,432	(12,786)	10,400	42,228

[Supplementary information on the changes in the financial position]

(1)Changes in the financial position

Total assets decreased by ¥3,239 million from the end of the fiscal year ended March 31, 2004 to ¥276,461 million, mainly due to the decrease in investment securities as a result of fall in market prices of possessed stocks.

Liabilities decreased by ¥189 million from the end of the fiscal year ended March 31, 2004 to ¥183,106 million. Shareholders' equity decreased by ¥3,019 million from the end of the fiscal year ended March 31, 2004 to ¥91,692 million, primarily due to the decrease in net unrealized gains (losses) on securities.

(2)Cash flows

Net cash provided by operating activities was ¥488 million, primarily reflecting the income before income taxes and depreciation and amortization. Net cash used in investing activities was ¥2,132 million, mainly due to payments for acquisition of fixed assets. Net cash provided by financing activities was ¥1,873 million. This reflected mainly proceeds from long-term borrowings.

(Reference)

Consolidated Business Forecast for the Fiscal Year ending March 31, 2005 (From April 1, 2004 to March 31, 2005)

	Sales	Recurring Income	Net Income
	Millions of yen	Millions of yen	Millions of yen
Interim period ending September 30, 2004	98,500	4,850	2,550
Fiscal Year ending March 31, 2005	200,000	10,400	5,300

(Reference) Projected Earnings per Share for the Fiscal Year ending March 31, 2005: 81.95 yen

[Supplementary information on the business forecasts]

The Japanese economy is anticipated to remain in the uncertainly, due to the concern in appreciation of yen and rise of interest rate arising from the expectation of economic recovery. Under such circumstances, we will strive to improve the business performance by focusing on development of new products continually and increasing and strength of productive capacity of each division.

There is no amendment to the forecast announced on May 20, 2004.

✕The above forecasts are based on the information available to the management as of the date of this report. The actual results may be different from these forecasts due to various factors occurring hereafter.

Consolidated Balance Sheets

(Unit: Millions of yen)

Account	Three months ended June 30, 2004		Fiscal Year ended March 31, 2004		Increase (decrease)	Three months ended June 30, 2003	
	Amount	%	Amount	%	Amount	Amount	%
(ASSETS)							
Current assets	<u>124,237</u>	44.9	<u>124,934</u>	44.7	<u>(696)</u>	<u>113,855</u>	44.9
Cash and bank deposits	44,476		45,241		(764)	33,197	
Trade notes and accounts receivable	41,732		41,524		207	43,307	
Inventories	32,335		32,541		(206)	32,056	
Deferred tax assets	1,479		1,734		(225)	1,941	
Others	4,419		4,100		319	3,490	
Allowance for doubtful accounts	(205)		(208)		3	(137)	
Fixed assets	<u>152,223</u>	55.1	<u>154,767</u>	55.3	<u>(2,543)</u>	<u>139,614</u>	55.1
Tangible fixed assets	<u>95,425</u>	34.5	<u>94,004</u>	33.6	<u>1,420</u>	<u>92,619</u>	36.5
Buildings and structures	42,256		40,545		1,711	40,726	
Machinery, equipment and vehicles	22,728		21,018		1,710	20,089	
Land	22,461		22,456		4	22,463	
Construction in progress	3,940		6,143		(2,203)	6,014	
Others	4,038		3,840		197	3,324	
Intangible fixed assets	<u>945</u>	0.4	<u>1,012</u>	0.4	<u>(67)</u>	<u>1,205</u>	0.5
Consolidation adjustments	15		54		(38)	169	
Others	930		958		(28)	1,035	
Investments and other assets	<u>55,852</u>	20.2	<u>59,749</u>	21.3	<u>(3,896)</u>	<u>45,789</u>	18.1
Investment securities	38,910		42,522		(3,612)	29,106	
Long-term loans receivable	2,443		2,843		(400)	2,636	
Deferred tax assets	206		193		12	193	
Lease deposits	11,766		11,774		(7)	11,867	
Others	3,174		3,085		89	2,658	
Allowance for doubtful Accounts	(647)		(670)		22	(672)	
Total assets	276,461	100.0	279,701	100.0	(3,239)	253,469	100.0

(Note) Increase (decrease) represents the comparison between the three months ended June 30, 2004 and the fiscal year ended March 31, 2004.

Consolidated Balance Sheets

(Unit: Millions of yen)

Account	Three months ended June 30, 2004		Fiscal Year ended March 31, 2004		Increase (decrease)	Three months ended June 30, 2003	
	Amount	%	Amount	%	Amount	Amount	%
(LIABILITIES)							
Current liabilities	<u>94,535</u>	34.2	<u>96,363</u>	34.4	<u>(1,828)</u>	<u>86,702</u>	34.2
Trade notes and accounts payables	28,049		29,048		(998)	28,795	
Shorts-term bank loans	35,298		35,503		(204)	35,052	
Current portion of bonds	10,000		10,000		-	-	
Other payables	3,930		4,769		(838)	3,630	
Income taxes payable	1,300		1,580		(280)	1,098	
Accrued bonuses	722		1,444		(722)	864	
Allowance for price reduction	-		-		-	1,250	
Notes payables for plant and equipment	3,985		4,207		(222)	5,423	
Commercial paper	7,000		6,500		500	7,000	
Others	4,247		3,310		937	3,587	
Non-current liabilities	<u>88,570</u>	32.0	<u>86,931</u>	31.1	<u>1,638</u>	<u>80,083</u>	31.6
Bonds	26,000		26,000		-	36,000	
Convertible- bonds-type bonds with stock acquisition rights	14,000		14,000		-	-	
Long-term borrowings	36,922		34,183		2,739	37,099	
Deferred tax liabilities	5,309		6,688		(1,379)	1,410	
Accrued pension and severance cost	2,714		2,528		186	2,219	
Others	3,623		3,531		91	3,354	
Total Liabilities	183,106	66.2	183,295	65.5	(189)	166,786	65.8
(MINORITY INTERESTS)							
Minority interests	1,662	0.6	1,693	0.6	(31)	1,786	0.7
(SHAREHOLDERS' EQUITY)							
Common stock	28,663	10.4	28,663	10.2	-	28,663	11.3
Additional paid-in capital	29,972	10.8	29,972	10.7	-	29,972	11.8
Retained earnings	31,018	11.2	30,610	10.9	408	28,583	11.3
Net unrealized gains (losses) on securities	10,390	3.8	12,462	4.5	(2,072)	4,272	1.7
Foreign currency translation adjustments	(7,835)	(2.8)	(6,489)	(2.3)	(1,345)	(6,130)	(2.4)
Treasury stock	(515)	(0.2)	(506)	(0.1)	(9)	(463)	(0.2)
Total Shareholders' equity	91,692	33.2	94,711	33.9	(3,019)	84,896	33.5
Total Liabilities, minority interests and shareholders' equity	276,461	100.0	279,701	100.0	(3,239)	253,469	100.0

(Note) Increase (decrease) represents the comparison between the three months ended June 30, 2004 and the fiscal year ended March 31, 2004.

Consolidated Statements of Income

(Unit: Millions of yen)

Account	Three months ended June 30, 2004		Three months ended June 30, 2003		Increase (decrease) Amount	Fiscal Year ended March 31, 2004	
	Amount	Ratio	Amount	Ratio		Amount	Ratio
Net sales	47,271	100.0	46,191	100.0	1,080	188,700	100.0
Cost of sales	33,927	71.8	33,006	71.5	921	137,153	72.7
Gross profit	13,343	28.2	13,185	28.5	158	51,547	27.3
Selling, general and administrative expenses	9,946	21.0	9,453	20.5	492	38,989	20.6
Operating income	3,397	7.2	3,731	8.0	(334)	12,557	6.7
Non-operating income	370	0.8	302	0.7	68	963	0.5
Interest income	29		40		(10)	160	
Dividend income	111		92		18	184	
Gain on sales of investment securities	-		-		-	139	
Exchange gains	154		-		154	-	
Others	75		169		(93)	479	
Non-operating expenses	604	1.3	790	1.7	(186)	3,982	2.1
Interest expenses	387		407		(20)	1,635	
Equity in losses of an affiliate	175		216		(41)	771	
Exchange losses	-		153		(153)	1,429	
Others	40		12		28	145	
Recurring income	3,164	6.7	3,243	7.0	(79)	9,539	5.1
Extraordinary gains	61	0.1	168	0.4	(106)	573	0.3
Reversion of allowance for doubtful accounts	21		105		(84)	108	
Subsidies received	-		-		-	445	
Others	40		62		(21)	18	
Extraordinary losses	119	0.2	728	1.6	(608)	2,068	1.1
Loss on sales and disposals of fixed assets	18		189		(170)	427	
Loss on devaluation of investment securities	-		98		(98)	102	
Advanced depreciation deduction	-		-		-	445	
Abnormal manufacturing cost	67		91		(23)	271	
Bad debt loss	-		290		(290)	290	
Settlement by reconciliation regarding sales rights	-		-		-	272	
Others	33		58		(24)	256	
Net income before adjustment of taxes	3,106	6.6	2,683	5.8	422	8,043	4.3
Corporate, inhabitants and enterprise taxes	1,153	2.4	988	2.1	164	3,765	2.0
Adjustment for deferred taxes	274	0.6	188	0.4	86	85	0.1
Minority interests in net income of consolidated subsidiaries	-	-	17	0.1	(17)	-	-
Minority interests in net loss of consolidated subsidiaries	55	0.1	-	-	55	23	0.0
Net (Quarter) income	1,734	3.7	1,490	3.2	244	4,216	2.2

(Note) Increase (decrease) represents the comparison between the three months ended June 30, 2004 and the three months ended June 30, 2003.

Consolidated Statements of Cash Flows

(Unit: Millions of yen)

Account	Three months ended June 30, 2004	Three months ended June 30, 2003	Fiscal Year ended March 31, 2004
	Amount	Amount	Amount
Cash flows from operating activities			
Net income before adjustment for taxes	3,106	2,683	8,043
Depreciation and amortization	2,385	2,233	9,819
Amortization of consolidation adjustments	38	43	159
Equity in loss of an affiliate	175	216	771
Bad debt loss	-	290	290
Increase (decrease) in allowance for doubtful accounts	(21)	(82)	(13)
Interest and dividend income	(140)	(133)	(344)
Interest expenses	387	407	1,635
Exchange losses (gains)	(144)	(110)	502
Decrease (increase) in trade receivables	269	(482)	1,093
Decrease (increase) in inventories	96	(752)	(1,515)
Increase (decrease) in trade payables	(926)	1,642	2,172
Decrease (increase) in other assets	(700)	616	(981)
Increase (decrease) in other liabilities	(2,051)	(1,131)	(133)
Bonuses to directors and corporate auditors	(86)	(111)	(111)
Other non-operating income/expense and extraordinary income/losses	13	164	512
Subtotal	2,402	5,495	21,902
Interest and dividends received	90	89	261
Interest paid	(573)	(624)	(1637)
Other revenues	148	312	911
Other expenditures	(136)	(235)	(1,195)
Income taxes paid	(1,443)	(2,530)	(4,809)
Cash flows from operating activities	488	2,506	15,432
Cash flows from investing activities			
Deposits in time deposits	(742)	(965)	(3,064)
Proceeds from time deposits	1,717	406	3,117
Payments for purchases of securities	(119)	(13)	(516)
Proceeds from sales of securities	-	-	448
Payments for acquisition of fixed assets	(3,133)	(2,536)	(13,244)
Proceeds from sales of fixed assets	129	1	578
Lending of loans	(0)	(1)	(134)
Collections of loans receivable	15	12	53
Payments for investments in capital	-	(23)	(23)
Reimbursements of investments in capital	-	-	0
Cash flows from investing activities	(2,132)	(3,120)	(12,786)
Cash flows from financing activities			
Net increase (decrease) in short-term borrowings	670	(2,532)	(1,763)
Net increase (decrease) in commercial paper	500	-	(500)
Proceeds from long-term borrowings	4,400	3,164	6,126
Repayment of long-term borrowings	(2,553)	(1,556)	(7,734)
Proceeds from issuance of bonds	-	-	13,921
Payments for redemption of bonds	-	(2,000)	(2,000)
Payments for purchases of treasury stock	(9)	(12)	(54)
Repayments of lease obligations	(100)	(2)	(336)
Payments for dividends	(1,053)	(637)	(1,399)
Reimbursement of funds for redemption of convertible bonds	-	4,141	4,141
Cash flows from financing activities	1,873	564	10,400
Effect of exchange rate changes on cash and cash equivalents	(35)	123	(211)
Increase (decrease) in cash and cash equivalents	193	74	12,835
Balance of cash and cash equivalents at the beginning of the period	42,228	29,393	29,393
Balance of cash and cash equivalents at the beginning of the period in new consolidated subsidiary	19	-	-
Balance of cash and cash equivalents at the end of the period	42,441	29,467	42,228

(Segment information)

1. Segment information by business category

(1) Three months ended June 30, 2004 (From April 1, 2004 to June 30, 2004)

(Millions of yen)

	Medical	Pharmaceutical	Glass & Materials	Super-market	Other	Total	Eliminations /Corporate	Consolidated
Net sales and operating income								
Net sales								
(1) Sales to third parties	19,961	6,373	2,802	17,822	311	47,271	-	47,271
(2) Inter-segment sales and transfers	296	-	581	-	141	1,020	(1,020)	-
Total	20,258	6,373	3,384	17,822	452	48,291	(1,020)	47,271
Operating expenses	17,082	5,669	2,912	17,704	339	43,708	166	43,874
Operating income	3,175	704	472	118	113	4,583	(1,186)	3,397

(2) Three months ended June 30, 2003 (From April 1, 2003 to June 30, 2003)

(Millions of yen)

	Medical	Pharmaceutical	Glass & Materials	Super-market	Other	Total	Eliminations /Corporate	Consolidated
Net sales and operating income								
Net sales								
(1) Sales to third parties	19,688	5,716	2,727	17,953	105	46,191	-	46,191
(2) Inter-segment sales and transfers	116	-	665	-	155	937	(937)	-
Total	19,805	5,716	3,393	17,953	260	47,129	(937)	46,191
Operating expenses	16,292	5,092	2,985	17,683	208	42,263	196	42,459
Operating income	3,513	623	407	269	52	4,865	(1,134)	3,731

(3) Fiscal Year ended March 31, 2004 (From April 1, 2003 to March 31, 2004)

(Millions of yen)

	Medical	Pharmaceutical	Glass & Materials	Super-market	Other	Total	Eliminations /Corporate	Consolidated
Net sales and operating income								
Net sales								
(1) Sales to third parties	78,726	25,338	11,890	71,357	1,386	188,700	-	188,700
(2) Inter-segment sales and transfers	639	-	2,356	-	596	3,592	(3,592)	-
Total	79,365	25,338	14,247	71,357	1,983	192,292	(3,592)	188,700
Operating expenses	62,248	22,868	12,428	70,937	1,578	175,061	1,081	176,142
Operating income	12,117	2,470	1,818	420	404	17,231	(4,673)	12,557

- Note: 1. Classification of business categories and main products in each business category
 Business categories are classified based on the proximity in terms of purposes and manners of usage of the products in the market.
 Main products belonging to each business categories are as follows

Business category	Main products
Medical	Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets, etc.
Pharmaceutical	Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysate solution, and circulatory drugs, etc.
Glass & Materials	Glass for pharmaceutical containers, glass for thermos bottles, glass for lighting purposes, stoppers for plastic containers and rubber stoppers, etc.
Supermarket	Fresh meat and fish, vegetables, fruits, processed food, daily foods, frozen foods, general groceries and medicine, etc.
Other	Machinery for manufacture of medical equipment and real estate rental income, etc.

2. Operating expenses of "Eliminations/Corporate" for the three months ended June 30, 2004, the three months ended June 30, 2003 and the fiscal year ended March 31, 2004 included unallocated corporate costs of 1,186 million yen, 1,134 million yen and 4,673 million yen, respectively. The unallocated corporate costs consisted primarily of the parent companies' research and development costs and headquarters administration costs.

2. Segment information by geographical area

(1) Three months ended June 30, 2004 (From April 1, 2004 to June 30, 2004)

(Millions of yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales and operating income							
Net sales							
(1) Sales to third parties	43,981	1,731	1,430	128	47,271	-	47,271
(2) Inter-segment sales and transfers	2,755	65	0	2,401	5,223	(5,223)	-
Total	46,736	1,797	1,431	2,530	52,495	(5,223)	47,271
Operating expenses	42,413	1,827	1,358	2,443	48,042	(4,167)	43,874
Operating income (loss)	4,323	(29)	72	86	4,453	(1,055)	3,397

(2) Three months ended June 30, 2003 (From April 1, 2003 to June 30, 2003)

(Millions of yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales and operating income							
Net sales							
(1) Sales to third parties	43,382	1,023	1,350	434	46,191	-	46,191
(2) Inter-segment sales and transfers	2,478	95	-	2,074	4,648	(4,648)	-
Total	45,861	1,119	1,350	2,509	50,840	(4,648)	46,191
Operating expenses	40,981	1,240	1,374	2,259	45,856	(3,396)	42,459
Operating income (loss)	4,879	(121)	(23)	249	4,983	(1,252)	3,731

(3) Fiscal Year ended March 31, 2004 (From April 1, 2003 to March 31, 2004)

(Millions of yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales and operating income							
Net sales							
(1) Sales to third parties	176,373	4,707	5,922	1,696	188,700	-	188,700
(2) Inter-segment sales and transfers	9,609	377	27	8,470	18,485	(18,485)	-
Total	185,983	5,085	5,949	10,167	207,185	(18,485)	188,700
Operating expenses	169,172	5,265	5,833	9,755	190,026	(13,883)	176,142
Operating income (loss)	16,810	(180)	116	412	17,159	(4,602)	12,557

- Note:
- Classification of countries or areas is based on geographical proximity.
 - The major countries and areas included in each geographical area are as follows
 - America The United States of America and Brazil
 - Europe Belgium
 - Asia China and Thailand
 - Operating expenses of "Eliminations and Corporate" for the three months ended June 30, 2004 and the three months ended June 30, 2003 and the fiscal year ended March 31, 2004 included unallocated corporate costs of 1,186 million yen, 1,134 million yen and 4,673 million yen, respectively. The unallocated corporate costs consisted primarily of the parent company's research and development costs and the headquarters administration costs.

3. Overseas sales

(1) Three months ended June 30, 2004 (From April 1, 2004 to June 30, 2004)

(Millions of yen)

	America	Europe	Asia	Total
1. Overseas sales	6,596	4,620	1,080	12,297
2. Consolidated net sales				47,271
3. Percentage of overseas sales against consolidated net sales (%)	13.9%	9.8%	2.3%	26.0%

(2) Three months ended June 30, 2003 (From April 1, 2003 to June 30, 2003)

(Millions of yen)

	America	Europe	Asia	Total
1. Overseas sales	4,581	4,495	1,446	10,523
2. Consolidated net sales				46,191
3. Percentage of overseas sales against consolidated net sales (%)	9.9%	9.8%	3.1%	22.8%

(3) Fiscal Year ended March 31, 2004 (From April 1, 2003 to March 31, 2004)

(Millions of yen)

	America	Europe	Asia	Total
1. Overseas sales	21,136	18,861	5,425	45,422
2. Consolidated net sales				188,700
3. Percentage of overseas sales against consolidated net sales (%)	11.2%	10.0%	2.9%	24.1%

- Note:
- Classification of countries or areas is based on geographical proximity.
 - The major countries and areas included in each geographical area are as follows
 - America The United States of America, Canada and Brazil
 - Europe Belgium, Denmark and Germany
 - Asia China, Taiwan and Thailand
 - Overseas sales represent those of the Company and the consolidated subsidiaries to countries and areas outside of Japan.

Production, Orders received and Sales

1. Production

(Millions of yen)

Business segment	Three months ended June 30, 2004		Three months ended June 30, 2003		Fiscal year ended March 31, 2004	
	Amount Produced	Ratio against the same period of the previous fiscal year (%)	Amount Produced	Ratio against the same period of the previous fiscal year (%)	Amount Produced	Ratio against the same period of the previous fiscal year (%)
Medical	14,669	0.1	14,656	-	57,577	0.2
Pharmaceutical	6,467	6.0	6,099	-	24,785	7.2
Glass & Materials	836	(12.3)	953	-	3,829	12.7
Other	105	1.8	103	-	720	(41.9)
Total	22,078	1.2	21,812	-	86,913	2.0

- Note: 1. Amounts produced are calculated based on average selling prices.
 2. The above amounts are after eliminations of the intersegment transactions.
 3. The above amounts do not include the related consumption taxes.

2. Orders received

Since we adopt the production system based on estimated orders, there is nothing applicable hereto regarding the amount and the balance of orders received.

3. Sales

(Millions of yen)

Business segment	Three months ended June 30, 2004		Three months ended June 30, 2003		Fiscal year ended March 31, 2004	
	Amount Produced	Ratio against the same period of the previous fiscal year (%)	Amount Produced	Ratio against the same period of the previous fiscal year (%)	Amount Produced	Ratio against the same period of the previous fiscal year (%)
Medical	19,961	1.4	19,688	-	78,726	3.6
Pharmaceutical	6,373	11.5	5,716	-	25,338	15.3
Glass & Materials	2,802	2.8	2,727	-	11,890	7.5
Supermarket	17,822	(0.7)	17,953	-	71,357	2.6
Other	311	194.8	105	-	1,386	(21.2)
Total	47,271	2.3	46,191	-	188,700	4.6

- Note: 1. The above amounts are after eliminations of the intersegment transactions.
 2. The above amounts do not include the related consumption taxes.